Calcium Carbonate + nelfinavir + lamivudine + loperamide + nelfinavir + lamivudine + zidovudine
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diarrhea
Conditions
Diarrhea
Trial Timeline
Jan 1, 2003 → Aug 1, 2003
NCT ID
NCT00650637About Calcium Carbonate + nelfinavir + lamivudine + loperamide + nelfinavir + lamivudine + zidovudine
Calcium Carbonate + nelfinavir + lamivudine + loperamide + nelfinavir + lamivudine + zidovudine is a phase 3 stage product being developed by Pfizer for Diarrhea. The current trial status is terminated. This product is registered under clinical trial identifier NCT00650637. Target conditions include Diarrhea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00650637 | Phase 3 | Terminated |
Competing Products
20 competing products in Diarrhea